Teva Wins ratiopharm, As it Moves to Solidify its EU Position
The purchase of the privately held ratiopharm Group solidifies Teva's number one position in the European generics industry and fits well with its goal of expanding the gap between itself and competitors. Importantly, it gives Teva a firm standing in Germany, where it had been a minor player.
You may also be interested in...
It's time for The IN VIVO Blog's Third Annual Deal of the Year competition. This year, awards will be presented in three categories to highlight the most interesting and creative deal making solutions of 2010.
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
In Vivo presents another quarterly review of pharmaceutical/biotechnology dealmaking - for the first quarter of 2010. Our data come from Elsevier's Strategic Transactions. During the first quarter of 2010, biopharma companies raised $2.6 billion through 94 transactions, slightly better than last year's opening, but a decrease of 43% from Q4 2009. Early venture capital rounds were the most popular type of financings, followed closely by follow-on public offerings and private investments in public companies, but FOPOs clearly brought in the most money, $1.1 billion.With less than half the M&A deal volume of the previous quarter - however, about the same dollar figure - Q1 2010's 12 transactions brought in $7.1 billion.